Lightnews — Scholar-powered news

Negative Screening Results and Colorectal Cancer

September 17, 2025 at 2:55 PM

Mike Pishvaian

@mpishvaian.bsky.social

@hopkinspress.bsky.social
#GIOnc

➡️Pancreatic enzyme insufficiency is very challening for patients with #pancreaticcancer (and difficult for their physicians to manage)
✅We need dieticians like Mary-Eve Brown to help us manage these patients

February 8, 2025 at 8:33 PM

Alfonso De Stefano

@adestefano.bsky.social

Interesting paper on #JAMA Oncology: long-term colorectal cancer incidence according to negative colonoscopy screening results and individuals’ risk profiles #OncSky #GIonc
ja.ma/41o4Eyk

This cohort study compares the long-term risk of colorectal cancer incidence and mortality among individuals receiving a negative colonoscopy screening result with those not undergoing endoscopy.

ja.ma

December 7, 2024 at 3:28 PM

drtimos.bsky.social

@drtimos.bsky.social

🚀 Get the #Oncology buzz from #ASCOGI25!

Top themes: #Efficacy 16.2%, #ClinicalTrials 16.1%, #Data 15.9%. #CRCsm & #GIOnc dominate, with #ctDNA & #Immunotherapy hot topics. 📊🩺

Download our full report! http://dlvr.it/TLKG41
@ASCO

#SocialListening #LucidQuest

403. That’s an error. We're sorry, but you do not have access to this page. That’s all we know.

Nivolumab/Ipilimumab vs Chemotherapy With or Without Targeted Agents in MSI-H or dMMR Metastatic Colorectal Cancer

June 12, 2025 at 6:06 PM

Alfonso De Stefano

@adestefano.bsky.social

Nivolumab/Ipilimumab vs Chemotherapy With or Without Targeted Agents in MSI-H or dMMR Metastatic Colorectal Cancer #OncSky #GIonc @ascopost.bsky.social

ascopost.com/news/decembe...

As reported in The New England Journal of Medicine by Andre et al, interim analysis of the phase III CheckMate 8HW trial has shown that nivolumab plus ipilimumab prolonged progression-free survival vs...

ascopost.com

December 13, 2024 at 6:43 AM

Alfonso De Stefano

@adestefano.bsky.social

Many thanks to @mpishvaian.bsky.social to share his top abstract titles of the upcoming #GI25 @ascocancer.bsky.social #GIonc

Mike Pishvaian @mpishvaian.bsky.social · Jan 11

#GI25 @ascocancer.bsky.social
Starting with #PancreaticCancer and Ras⛔️
Actually only2⃣titles I saw:
1⃣Ignacio Garrido-Laguna🗣️ctDNA🩸changes in the Ph1 trial of the Ras(on)⛔️RMC-6236 Abs 722; Poster#H10

2⃣Alex Spira🗣️a Ph1 trial of the G12D specific⛔️RMC-9805 Abs 724; Poster#H12

January 11, 2025 at 7:01 PM

Dr Joseph McCollom DO

@realbowtiedoc.bsky.social

Happy Thanksgiving to all who celebrate. #Gratitude has value year round 📅 and worldwide 🌎 #pallonc #supponc #GIonc

November 28, 2024 at 9:43 PM

Dr Joseph McCollom DO

@realbowtiedoc.bsky.social

A a high yield #GIonc review of #IO agents in #hpbcsm

#IO has transformed treatment, ⬆️ #OS and creating new #SoC.

💉 Reviews #regimens
🤝 Discusses #synergy with chemo
🚧 Highlight unmet #needs

🔗: cancertreatmentreviews.com/article/S030...

@oncoalert.bsky.social
@weoncologists.bsky.social

The present and the future of immunotherapy in hepatocellular carcinoma and biliary tract cancers

Hepatobiliary malignancies represent a growing global health burden, with rising incidence rates worldwide [1–3]; however, recent years have witnessed remarkable therapeutic breakthroughs that are res...

cancertreatmentreviews.com

July 2, 2025 at 12:56 PM

OncoDaily

@oncodaily.bsky.social

New Paper Alert: Zanidatamab Plus Chemotherapy for HER2-Positive Gastro-Oesophageal Adenocarcinoma

oncodaily.com/oncolibrary/...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Zanidatamab #Chemotherapy #GastroOesophagealAdenocarcinoma #GIOnc

Zanidatamab Plus Chemotherapy for HER2-Positive GEA

Zanidatamab plus chemotherapy's potential in treating HER2-positive advanced gastro-oesophageal adenocarcinoma with promising efficacy

July 16, 2025 at 10:27 PM

drtimos.bsky.social

@drtimos.bsky.social

🚀 Get the #Oncology buzz from #ASCOGI25!

Top themes: #Efficacy 16.2%, #ClinicalTrials 16.1%, #Data 15.9%. #CRCsm & #GIOnc dominate, with #ctDNA & #Immunotherapy hot topics. 📊🩺

Download our full report! http://dlvr.it/TLBMqn
@ASCO

#SocialListening #LucidQuest

We're sorry, but you do not have access to this page. That’s all we know.

Triple Combination of Encorafenib, Cetuximab, and Nivolumab in MSS BRAFV600E Metastatic Colorectal Cancer - OncoDaily

June 5, 2025 at 2:58 PM

OncoDaily

@oncodaily.bsky.social

Triple Combination of Encorafenib, Cetuximab, and Nivolumab in MSS BRAFV600E Metastatic Colorectal Cancer

oncodaily.com/oncolibrary/...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Encorafenib #Cetuximab #Nivolumab #ColorectalCancer #CRC #GIOnc

Triplet of encorafenib, cetuximab, and nivolumab shows 50% response and 22-month OS in MSS BRAFV600E mCRC.

Yan Leyfman: New Insights in Multiple Myeloma Care - OncoDaily

September 30, 2025 at 10:00 PM

Dr Joseph McCollom DO

@realbowtiedoc.bsky.social

Excited to report on #GI25 for @oncoalert.bsky.social. Stay tuned for the best in #GIonc summaries for each day of the conference.

American Society of Clinical Oncology @ascocancer.bsky.social · Jan 21

The #GI25 abstracts are now available! Late-Breaking Abstracts (LBAs) will be released at 7:00 AM PT on their day of presentation. Check out the latest practice-changing science in GI cancers here: brnw.ch/21wQ9Ql

January 22, 2025 at 5:09 PM

Dr Joseph McCollom DO

@realbowtiedoc.bsky.social

Love seeing more representation from Hospice&PalliativeCare CanSky OncoSky and MedSky on this beautiful platform.

Let me know who I should be following and who loves to engage.

pallonc supponc GIonc

September 27, 2023 at 11:35 AM

Dr Joseph McCollom DO

@realbowtiedoc.bsky.social

Not every place recognizes your value in that moment. Never abandon your dream and surround yourself with supporters. I didn't match for #MedOnc my application year, but now I'm honored to serve #GIonc and #pallonc patients. #MedEd #MedSky #ShareRejection

Fumiko Ladd Chino, MD FASCO @fumikochino.bsky.social · Jul 7

#medSky #medstudentSky reminder: Failure is part success.

Today I was organizing some papers and found these 3 #rejection letters from medical school from Stanford, Yale, and UCSF.

Normalizing rejection is just as important as sharing your wins. #ShareyourRejection

July 7, 2025 at 8:19 AM

OncoDaily

@oncodaily.bsky.social

New Insights in Multiple Myeloma Care - Yan Leyfman

@yleyfman.bsky.social

oncodaily.com/insight/359908

#Cancer #GIOnc #MedEd #MedX #MedNews #Health #Medicine #OncoDaily #Oncology #MM #Myeloma

Yan Leyfman: New Insights in Multiple Myeloma Care / Alexandria Jensen, Amelia Jones, Andrew Rezvani, David Miklos, Dilek Uzun, Felipe Araya Ventura, Hitomi

September 1, 2025 at 9:42 PM

Dr Joseph McCollom DO

@realbowtiedoc.bsky.social

Don't forget to sign up for the
@oncoalert.bsky.social Newsletter to never miss an update 🔗: oncoalert.m-pages.com/nhMpwe/oncoa...

Neoantigen (SEL) #TIL in #GIonc showing responses when #IO added. Early promise for #crcsm with hopes to expand in another trial.

April 4, 2025 at 11:04 PM

drtimos.bsky.social

@drtimos.bsky.social

🚀 Get the #Oncology buzz from #ASCOGI25!

Top themes: #Efficacy 16.2%, #ClinicalTrials 16.1%, #Data 15.9%. #CRCsm & #GIOnc dominate, with #ctDNA & #Immunotherapy hot topics. 📊🩺

Download our full report! http://dlvr.it/TL3DDs
@ASCO

#SocialListening #LucidQuest

Three new Pan-Asian-adapted guidelines at ESMO Asia Congress

May 29, 2025 at 2:58 PM

Dr Joseph McCollom DO

@realbowtiedoc.bsky.social

#GI26 is the perfect conference to showcase the best of #GIonc Don't miss out submit today!
@crisbergerot.bsky.social
@realbowtiedoc.bsky.social
@tingtingzhang.bsky.social
@ericroeland.bsky.social
@mazietsangmd.bsky.social
@ascocancer.bsky.social
@oncbrothers.bsky.social

American Society of Clinical Oncology @ascocancer.bsky.social · Sep 5

Hey, don’t forget to submit that #GI26 abstract! It’s your time to shine and help shape the future of GI cancer care with your #gicsm study in progress or a late-stage clinical trial.

Abstracts are due Sept. 9 at 11:59 p.m. (ET). Learn more: brnw.ch/21wVvcH

September 7, 2025 at 11:14 PM

Alfonso De Stefano

@adestefano.bsky.social

Three new Pan-Asian-Adapted Guidelines from #ESMOAsia2024 #BTC #OncSky #GIonc dailyreporter.esmo.org/esmo-asia-co...

The latest tumour types covered in the ESMO PAGAs are biliary tract cancers, oncogene-addicted metastatic NSCL cancer and epithelial ovarian cancer

dailyreporter.esmo.org

December 8, 2024 at 12:01 PM

drtimos.bsky.social

@drtimos.bsky.social

🚀 Get the #Oncology buzz from #ASCOGI25!

Top themes: #Efficacy 16.2%, #ClinicalTrials 16.1%, #Data 15.9%. #CRCsm & #GIOnc dominate, with #ctDNA & #Immunotherapy hot topics. 📊🩺

Download our full report! http://dlvr.it/TKcrzV
@ASCO

#SocialListening #LucidQuest

403. That’s an error. We're sorry, but you do not have access to this page. That’s all we know.

May 7, 2025 at 6:05 PM

drtimos.bsky.social

@drtimos.bsky.social

🚀 Get the #Oncology buzz from #ASCOGI25!

Top themes: #Efficacy 16.2%, #ClinicalTrials 16.1%, #Data 15.9%. #CRCsm & #GIOnc dominate, with #ctDNA & #Immunotherapy hot topics. 📊🩺

Download our full report! http://dlvr.it/TN4ly5
@ASCO

#SocialListening #LucidQuest

Bitly is dedicated to making the internet a safer place for everyone. Use the site preview above to make sure the link takes you where you expect.